Travere Therapeutics reported net product sales of $54.6 million for the second quarter of 2021. The company is on track to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021. The pivotal PROTECT Study of sparsentan in IgA nephropathy is on track to report topline data from the interim 36-week proteinuria endpoint in August 2021.
The Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021.
The Phase 3 PROTECT Study of sparsentan in IgA nephropathy (IgAN) completed patient enrollment in the second quarter of 2021; topline data from the 36-week interim proteinuria analysis are on track for August 2021.
Net product sales for the second quarter 2021 were $54.6 million, compared to $48.4 million for the same period in 2020.
Cash, cash equivalents and marketable securities, as of June 30, 2021, totaled $522.8 million.
Travere Therapeutics expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 and anticipates topline efficacy data from the 36-week interim proteinuria endpoint analysis from the PROTECT Study in August 2021.
Analyze how earnings announcements historically affect stock price performance